338 related articles for article (PubMed ID: 26670274)
21. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.
Ohem J; Hradsky O; Zarubova K; Copova I; Bukovska P; Prusa R; Malickova K; Bronsky J
Dig Dis; 2018; 36(1):40-48. PubMed ID: 28817809
[TBL] [Abstract][Full Text] [Related]
22. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.
Armuzzi A; Felice C; Papa A; Marzo M; Pugliese D; Andrisani G; Federico F; De Vitis I; Rapaccini GL; Guidi L
J Crohns Colitis; 2013 Dec; 7(12):e623-9. PubMed ID: 23810678
[TBL] [Abstract][Full Text] [Related]
23. Effect of intestinal resection on quality of life in Crohn's disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Sparrow MP; Florin TH; Gibson PR; Debinski H; Gearry RB; Macrae FA; Leong RW; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
J Crohns Colitis; 2015 Jun; 9(6):452-62. PubMed ID: 25855073
[TBL] [Abstract][Full Text] [Related]
24. Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.
Lasson A; Strid H; Ohman L; Isaksson S; Olsson M; Rydström B; Ung KA; Stotzer PO
J Crohns Colitis; 2014 Aug; 8(8):789-95. PubMed ID: 24418661
[TBL] [Abstract][Full Text] [Related]
25. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
[TBL] [Abstract][Full Text] [Related]
26. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
Ward MG; Warner B; Unsworth N; Chuah SW; Brownclarke C; Shieh S; Parkes M; Sanderson JD; Arkir Z; Reynolds J; Gibson PR; Irving PM
Aliment Pharmacol Ther; 2017 Jul; 46(2):150-161. PubMed ID: 28481014
[TBL] [Abstract][Full Text] [Related]
27. Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn's Disease.
Liu R; Guo Z; Cao L; Wang Z; Gong J; Li Y; Zhu W
Dis Colon Rectum; 2019 Mar; 62(3):318-326. PubMed ID: 30451756
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with infliximab and thiopurine compared to infliximab monotherapy in maintaining remission of postoperative Crohn's disease.
Sakuraba A; Okamoto S; Matsuoka K; Sato T; Naganuma M; Hisamatsu T; Iwao Y; Ogata H; Kanai T; Hibi T
Digestion; 2015; 91(3):233-8. PubMed ID: 25823572
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin.
Nogueira IM; Miszputen SJ; Ambrogini O; Artigiani-Neto R; Carvente CT; Zanon MI
Arq Gastroenterol; 2013 Apr; 50(2):130-7. PubMed ID: 23903623
[TBL] [Abstract][Full Text] [Related]
30. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
[TBL] [Abstract][Full Text] [Related]
31. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
[TBL] [Abstract][Full Text] [Related]
33. Correlation Between Calprotectin and Modified Rutgeerts Score.
Lopes S; Andrade P; Afonso J; Rodrigues-Pinto E; Dias CC; Macedo G; Magro F
Inflamm Bowel Dis; 2016 Sep; 22(9):2173-81. PubMed ID: 27482974
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
35. Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's Disease.
Veyre F; Boschetti G; Meunier C; Cuerq C; Gay C; Charlois AL; Duclaux-Loras R; Danion P; Cotte E; Kepenekian V; Mialon A; Faure M; Roblin X; Flourie B; Nancey S
Dig Dis Sci; 2021 Dec; 66(12):4429-4435. PubMed ID: 33387123
[TBL] [Abstract][Full Text] [Related]
36. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors.
Fay S; Ungar B; Paul S; Levartovsky A; Yavzori M; Fudim E; Picard O; Eliakim R; Ben-Horin S; Roblin X; Kopylov U
Inflamm Bowel Dis; 2017 Nov; 23(11):1924-1929. PubMed ID: 28837524
[TBL] [Abstract][Full Text] [Related]
37. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
38. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
Drobne D; Bossuyt P; Breynaert C; Cattaert T; Vande Casteele N; Compernolle G; Jürgens M; Ferrante M; Ballet V; Wollants WJ; Cleynen I; Van Steen K; Gils A; Rutgeerts P; Vermeire S; Van Assche G
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):514-521.e4. PubMed ID: 25066841
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
[TBL] [Abstract][Full Text] [Related]
40. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Selvaraj F; Princen F; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Gearry RB; Selby W; Bell SJ; Brown SJ; Connell WR
J Crohns Colitis; 2018 May; 12(6):653-661. PubMed ID: 29385469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
